Bio-Hub Agenda
The BioHub Agenda is led by Lxbio and involves the collaboration of four promoters (2 companies and 2 Research and Technology Organizations) which complement each other, to the extent that their activities are at different stages of the value chain of biopharmaceutical development.
The Consortium has outlined a set of activities that it believes will enable the development of valuable knowledge.
These activities will embrace different areas of work, namely:
- Clinical validation and production of bacteriophage cocktails and small domain antibodies, in Phase I, II/III studies;
- Construction and implementation of a production unit for the development and manufacturing of innovative biopharmaceuticals;
- Development of qualification and internationalization strategies oriented towards the promotion of new bioproducts that will be manufactured in the new production unit;
- Plan for dissemination and promotion of the advances and results of the different subprojects/activities.
The Bio-Hub Innovation Agenda will be led by the Lxbio entity, which has revealed all the technical capabilities essential to its leadership, from the development to the implementation phases of the project. As a promoter, Lx Bio will be responsible for the entire process of financing and managing the construction / qualification of the production unit for the development of biopharmaceuticals products.
Technophage has a strong scientific and management team, with training mainly in the areas of Biomedicine, Pharmacy, and Drug Development. It has gathered know-how in the pharmaceutical sector, over the last few years, as a result of various projects developed, of which the TP-102 study (Research and Development of new therapeutic products with antibacterial activity for the treatment and prevention of bacterial infections of diabetic foot ulcers, with a view to complementing classical antibiotic therapy of chemical origin) and TP-122 (Research and Development of a phage-based technology as therapy and prevention for bacterial lung infections), which will continue in the progress presented Agenda.
VectorB2B resulted from the shared initiative of seven entities: Faculty of Pharmacy of the University of Lisbon, Faculty of Medicine of the University of Lisbon, Faculty of Veterinary Medicine of the University of Lisbon, University of Coimbra, Medinfar, BeVaG and TechnoPhage. This collaborative laboratory can provide highly qualified services from the laboratory to the patient (“from bench to bedside”, B2B). At its core, VectorB2B provides integrated services in drug discovery, project design and implementation, pre-clinical research (efficacy and ADME), contract production and clinical trial management.
To complete the Consortium, the proposed Innovation Agenda will have a second non-Business entity of the R&I System, Faculdade de Farmácia da Universidade de Lisboa (FFUL). Founded in 1836, FFUL is currently among the most prestigious institutions of higher education in the country and has also been focused on the international panorama. In addition to its high-quality educational activity, FFUL today plays a major role in the context of national and international scientific activity. Over the years, it has been positioning itself to attract external investment for R&D projects, in various scientific areas and in a broad spectrum of typologies, both as a promoter and partner, which translates into a diversified portfolio of projects.
